Wednesday, August 15, 2018
Company News: Page (1) of 1 - 06/13/18 Email this story to a friend. email article Print this page (Article printing at page facebook
Migraine Impacts Employers in both Health Care Spend and Lost Productivity Per Integrated Benefits Institute Study

(June 13, 2018)

A 1,000-person firm could lose more than $80,000 annually to migraine-related health costs and lost work time

San Francisco, June 13, 2018 (GLOBE NEWSWIRE) -- SAN FRANCISCO – June 13, 2018 – Employers bear more than the costs of medical treatments for employees who suffer with migraine—there are also substantial costs due to lost work time. This is among the findings in a new study released by the Integrated Benefits Institute (IBI), a non-profit focused on health and productivity.

Migraine is a neurological disease marked by intense, frequent headaches that can last for hours, often accompanied by other symptoms such as nausea and sensitivity to light and sound. It affects nearly one in 10 men and one in five women in the U.S. workforce.

IBI’s analysis of Agency for Health Research and Quality (AHRQ) survey data found that from 2011 to 2015, employees treated for migraine had higher health care costs on average than employees without migraine treatments—a difference of about $2,000 per year. Employees treated for migraine also had an average of 2.2 more sick days per year, at a cost of almost $600 in wages and benefits. The report also examines disability losses using claims data in IBI’s Health and Productivity Benchmarking database.

“Even though migraine is common, employers have not focused on it because the treatments have been relatively inexpensive. The productivity losses we found in this report should help a lot of companies understand the real impact it has on their bottom line—especially considering that migraine is both underdiagnosed and undertreated,” said Brian Gifford, PhD, Director, Research and Analytics for IBI. “Hopefully employers will take productivity into account when they consider adding new treatment options to their benefit plans and workplace policies that help people with migraine stay on the job. These can deliver not only cost savings for the company, but improved health and well-being for their employees.”

Additional findings in IBI’s analysis include:

  • Employees who take short-term disability leave for migraine miss an average of 38 work days per episode—an economic loss to their employer of about $10,400. If a migraine claimant continues into the long-term disability system—which typically commences after short-term benefits end and can continue until a claimant reaches retirement age—the additional costs are about $37,000 per year.
  • Companies that offer health care benefits, paid sick days and disability insurance benefits can expect about $84,000 in annual migraine-related costs for every 1,000 people it employs. Nearly one-third of these costs are for lost work time due to migraine.
  • Disability claims for migraine may indicate a high risk of exit from the labor force. Sixty-three percent of long-term disability claims remained active and accruing lost work time after two years.
  • About one-third of employees treated for migraine also had obesity. Mood disorders, back pain, anxiety disorders, and hypertensive disease afflicted about one in five employees with migraine. Co-morbidities such as these may complicate efforts to help employees manage their conditions—and underscore the importance of coordinated care approaches.
  • The findings in this report likely undercount the productivity losses due to migraine. Fourteen percent of U.S. workers reported migraine, but only three percent received migraine treatment. Sick day absences for people with migraines who did not receive care for their condition needs further study.

Not included in this report—although previous studies suggest that the toll is substantial—is the impact of on-the-job performance (“presenteeism”) when a migraine attack occurs. “One of the things we found in an earlier migraine study was that employees with migraine and other severe headaches were more likely to report sick day absences and had more difficulty concentrating at work, working carefully, or producing work of good quality,” said Thomas Parry, PhD, IBI President. “The good news is that these difficulties were explained entirely by their frequency of headaches. This suggests that productivity issues can be relieved by helping migraine sufferers manage their condition.”

This study is part of IBI’s Health and Productivity Impact of Chronic Conditions Series developed to help employees manage chronic illnesses to reduce employers’ healthcare and disability costs. The analysis uses high-quality data to model healthcare, illness absence (i.e., sick days) and disability costs for populations of employees across different industries. The results provide a scalable cost benchmark that employers and their supplier partners can use to assess potential savings from reductions in the prevalence of a condition, costs of treatments, and illness-related absences and disability leaves. Past series have examined depression, back pain, rheumatoid arthritis and diabetes.

To request a copy of the report, please contact Dr. Parry via email, [email protected].

About Integrated Benefits Institute

As the leading research organization in health and productivity, the Integrated Benefits Institute Institute’s (IBI) work emphasizes that healthy, productive employees promote healthy business. Founded in 1995, IBI is an independent nonprofit serving more than 1,320 members employing 22 million people in the US. IBI provides unbiased research, insights and tools so employers and providers can make health decisions that positively impact people, productivity and performance (3Ps). For additional information, please visit and follow us on Twitter and LinkedIn.

# # #


Note to editors: A copy of the report is available for accredited media upon request by contacting Cary Conway.

CONTACT: Cary ConwayIntegrated Benefits Institute972[email protected]

Page: 1

Related Keywords:
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter

  • Neurovascular Devices Market High Revenue at USD 24,650 mn by 2023 | Therapeutic Application Hemorrhagic & Ischemic Strokes | Worldwide Segmentation by MRFR
  • New Report Identifies Unique Challenges for LGBT Community Facing Alzheimer's and Other Dementias
  • The Buck Institute, Insilico Medicine, and Juvenescence Found Napa Therapeutics to Develop Drugs to Impede Age-Related Disease,
  • The Buck Institute, Insilico Medicine, and Juvenescence Found Napa Therapeutics to Develop Drugs to Impede Age-Related Disease
  • Global Spinal Fusion Devices Market Expected to Reach USD 6.8 Billion By 2024: Zion Market Research

  • Biotest AG: Cytotect(R) CP prevents transmission of Cytomegalovirus (CMV) to the unborn baby in pregnant women who are infected with CMV for the first time
  • Citius Pharmaceuticals Successfully Raises $10 Million
  • ViewRay Announces Pricing of Public Offering of Common Stock
  • Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2012-2018: Deal trends, players, financials and forecasts
  • CASI Pharmaceuticals Announces Second Quarter And First Half 2018 Financial And Business Results

    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines